Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.

“We are pleased to welcome Rexahn Pharmaceuticals to the American Stock Exchange,” said Neal Wolkoff, Chairman and CEO, of the Amex. “We look forward to working with Rexahn in building increased awareness and visibility within the investment community.”

"As we continue to aggressively pursue our clinical development efforts, our listing on the Amex will increase shareholder value and provide expanded visibility to the investment community and capital markets, at large," stated Dr. Chang H. Ahn, Chairman and Chief Executive Officer of Rexahn. -- www.amex.com